Wed, Oct 22, 2014, 8:11 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Cytomedix, Inc. Message Board

suemadrids 21 posts  |  Last Activity: Oct 11, 2014 1:04 PM Member since: Jul 3, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    From 31 days to 4 days to cover...GLTA...

    by huskytrainer Sep 13, 2014 3:11 PM
    suemadrids suemadrids Oct 11, 2014 1:04 PM Flag

    down to 3 now!

    Sentiment: Strong Buy

  • Reply to

    Gotta luv proposal 4, you gotta work

    by donnyboyko Oct 8, 2014 5:53 PM
    suemadrids suemadrids Oct 11, 2014 1:03 PM Flag

    WOW. WOW, WOW, WOW!

    Sentiment: Strong Buy

  • Reply to

    Gotta luv proposal 4, you gotta work

    by donnyboyko Oct 8, 2014 5:53 PM
    suemadrids suemadrids Oct 11, 2014 1:02 PM Flag

    power luv affair!

    Sentiment: Strong Buy

  • Reply to

    Can't bury the facts...GLTA!

    by huskytrainer Sep 5, 2014 12:54 PM
    suemadrids suemadrids Oct 11, 2014 1:02 PM Flag

    Only the real deal facts1

    Sentiment: Strong Buy

  • TOZER DEAN Officer 09/12/2014 Buy direct 40,000 0.4500 166,700
    TOZER DEAN Officer 08/29/2014 Buy direct 40,000 0.3500 126,700
    SHALLCROSS STEVEN A Officer 08/26/2014 Buy direct 27,500 0.3800 79,500
    TOZER DEAN Officer 08/22/2014 Buy direct 38,700 0.3800 86,700
    SHALLCROSS STEVEN A Officer 08/20/2014 Buy direct 52,000 0.3900 52,000
    TOZER DEAN Officer 08/20/2014 Buy direct 48,000 0.3900 48,000
    ROSENDALE MARTIN P Officer 08/20/2014 Buy direct 25,000 0.4000 229,149

    Sentiment: Strong Buy

  • suemadrids by suemadrids Sep 24, 2014 7:02 PM Flag

    4. To amend the 2013 Equity Incentive Plan to increase the maximum number of shares of common stock which may be (i) issued to key employees as stock options in any calendar year, (ii) used for stock awards and/or stock unit awards intended to qualify as “performance-based” to any key employee in any calendar year under Section 162(m) of the Internal Revenue Code, and (iii) used for stock awards and/or stock unit awards, all as described in more detail in the Proxy Statement.

    Sentiment: Strong Buy

  • Insider
    Relation
    Last Date ▼
    Transaction Type
    OwnerType
    Shares Traded
    Last Price
    Shares Held

    TOZER DEAN
    Officer
    09/12/2014
    Buy
    direct
    40,000
    0.4500
    166,700

    TOZER DEAN
    Officer
    08/29/2014
    Buy
    direct
    40,000
    0.3500
    126,700

    SHALLCROSS STEVEN A
    Officer
    08/26/2014
    Buy
    direct
    27,500
    0.3800
    79,500

    TOZER DEAN
    Officer
    08/22/2014
    Buy
    direct
    38,700
    0.3800
    86,700

    SHALLCROSS STEVEN A
    Officer
    08/20/2014
    Buy
    direct
    52,000
    0.3900
    52,000

    TOZER DEAN
    Officer
    08/20/2014
    Buy
    direct
    48,000
    0.3900
    48,000

    ROSENDALE MARTIN P
    Officer
    08/20/2014
    Buy
    direct
    25,000
    0.4000
    229,149

    Sentiment: Strong Buy

  • suemadrids suemadrids Sep 17, 2014 8:29 PM Flag

    From 31 days to 4 days to cover...GLTA...
    Date
    Short Interest
    % Change
    Avg. Daily Share Volume
    Days to Cover
    Split
    Aug 29, 2014 2,384,323 -24.18 526,694 4.53
    Aug 15, 2014 3,144,582 4.46 100,316 31.35

    Sentiment: Strong Buy

  • Reply to

    Tozer & 750 million, now on Cytomedix team...

    by suemadrids Sep 17, 2014 8:16 PM
    suemadrids suemadrids Sep 17, 2014 8:27 PM Flag

    Simple facts enjoy...
    Under CMS' proposal for packaging in 2014, products like Dermagraft, Apligraf, and new products like Grafix, will become significantly disadvantaged, as all these products cost $1,500 or more. Under the current reimbursement system, hospitals are reimbursed $250 to $500 for the cost of the medical procedure, and are separately reimbursed for the cost of the graft for a total reimbursement of $2,000 to $2,225. The proposed bundled payment of $874 falls far short of the cost of the graft alone. We believe it will be difficult for these manufacturers to reduce their prices sufficiently to be attractive to caregivers in a bundled care environment. Two dermatology KOLs we've spoken with believe that the cost of manufacturing these grafts is in excess of $1,000. As we see it, that's going to create a very challenging sales environment for these two market leading products or new products like Grafix, and a major shift toward cheaper and similar efficacy products.

    CMS moving to a "pay for performance" model could eventually cap the entire reimbursement for "healing a DFU or VFU" to something like $3,000 or $4,000. Above we noted that Apligraf is eligible for reimbursement up to six times in the course of treating a VLU. Things are going to change in our view. The leading products are on their way out

    Sentiment: Strong Buy

  • suemadrids suemadrids Sep 17, 2014 8:24 PM Flag

    .
    Float: 24.76M
    % Held by Insiders 37.76%
    Interesting Insider August buys...GLTA!
    Aug 29, 2014 TOZER DEAN
    Officer direct Buy 0.35 40,000
    Aug 26, 2014 SHALLCROSS STEVEN A
    Officer direct Buy 0.38 27,500
    Aug 22, 2014 TOZER DEAN
    Officer direct Buy 0.38 38,700
    Aug 20, 2014 ROSENDALE MARTIN P
    Officer direct Buy 0.40 25,000
    Aug 20, 2014 TOZER DEAN
    Officer direct Buy 0.39 48,000
    Aug 20, 2014 SHALLCROSS STEVEN A
    Officer direct Buy 0.39 52,000 L

    Sentiment: Strong Buy

  • suemadrids suemadrids Sep 17, 2014 8:19 PM Flag

    Interesting who’s sponsoring one of Cytomedix CMS trials. Let’s connect the dots and GLTA?
    Study Title: A Multi-Center, Randomized Trial Comparing the Effectiveness of APIC-PRP to Control, when added to Standard of Care in the Treatment
    of Non-healing Diabetic Foot Ulcers
    Sponsor: Cytonics Corporation
    ClinicalTrials.gov Number: NCT02209662
    CMS Approval Date: 07/30/2014
    Life Technologies Acquires Cytonix
    July 31, 2009
    By a GenomeWeb staff reporter
    NEW YORK (GenomeWeb News) – Life Technologies recently acquired privately held Cytonix, a microfluidics technologies firm, the firm said earlier this week in its second-quarter earnings statement.
    Life Technologies provided few details about the acquisition of the Beltsville, Md.-based company. However, it said that it acquired the firm for its intellectual property related to its microfluidics-based digital polymerase chain reaction technology.
    Life Technologies also said that it plans to license the technology to partners as well as commercialize new products that can be used for applications ranging from next-generation sequencing library quantification to molecular diagnostic assays.
    Last year, Cytonix's wholly-owned subsidiary, Genomic Nanosystems, licensed to Sequenom exclusive rights to use its digital PCR methods for non-invasive, prenatal diagnostic testing and sample analysis on any platform. In addition, Sequenom obtained exclusive rights to use digital PCR in conjunction with mass spectrometry for all commercial, diagnostic, or research applications except second-generation sequencing

    Sentiment: Strong Buy

  • Reply to

    Tozer & 750 million, now on Cytomedix team...

    by suemadrids Sep 17, 2014 8:16 PM
    suemadrids suemadrids Sep 17, 2014 8:18 PM Flag

    Sheedy and Dejoria facts...
    Beneficial Ownership of Certain Beneficial Owners

    The following table sets forth information regarding the ownership of the Company’s common stock as of March 27, 2014.

    Name of Beneficial Owner Beneficial Ownership (1) Percent of Class (1)

    John Paul DeJoria 6,900,044 (2) 9.2%
    Charles E. Sheedy 7,363,798 (3) 9.7

    Sentiment: Strong Buy

  • Tozer sold ABH to Shire for 750 million…



    “ABH did a retrospective data analysis that showed that Dermagraft is cost effective after six months. That’s important to payers because their data show that people typically change insurance every two years. If a product doesn’t avoid cost before then, it won’t save the payer money”.



    Regenerative medicine company Advanced BioHealing is now part of Shire (NASDAQ:SHPGY), but before it was acquired last May, the Westport, Connecticut company was hours from pulling the trigger on an initial public stock offering.

    ABH’s wound healing product for diabetics had made the company profitable in less than three years, but it needed more cash. Dermagraft is a bioengineered skin substitute product consisting of human fibroblast cells on a scaffold. The product is used to treat diabetic foot ulcers. With Dermagraft sales growing, ABH executives last year concluded that they needed to build a second manufacturing facility at a cost of up to $100 million, said Dean Tozer, ABH’s senior vice president of corporate development. ABH was founded in 2004 and had raised $10.4 million in two rounds of venture financing. But the company’s investors were looking for an exit.

    Tozer said that discussions with private equity firms came close to a deal. But in the second half of 2010, management decided to pursue an IPO. The offering would have valued the company at more than $600 million. But on the morning of May 17, the day before ABH was expected to go public, the company instead announced it had been acquired by Shire for $750 million.



    Tozer spoke Tuesday in Chapel Hill, North Carolina at medtech11, the annual conference hosted by North Carolina medical technology group ibiliti. It was the first time he had spoken publicly since the company’s acquisition by Shire.

    The theme of medtech11 is “convergence” and Tozer offered insight on navigating through the regulatory process a product that is part medical device and part biological. He also offered tips on commercialization. Here are some highlights:

    Forget what you know. The U.S. Food and Drug Administration considers Dermagraft a device. The Centers for Medicare & Medicaid Services considers the product a biologic. European regulators classify it as a medicinal product. You can’t think about your product as being in a single category. You’ve got to be able to think about all of them. So Tozer’s advice is to forget what you know. “If your product is a convergence product, it doesn’t apply.”

    Find the right people. Because Dermagraft doesn’t fall into a single category, ABH needed to find the right people who could talk to the FDA and CMS. Finding the right people was also important for sales. The company established strong incentives for sales growth and the team met them. Since Dermagraft’s 2007 launch, sales had grown to $147 million in just three years.

    Leverage. ABH was in the enviable position to choose between either an IPO or a sale. With growing revenue and more than $35 million in profit, the company was a strong IPO candidate. Shire entered the picture late in the game in the weeks before the company was set to enter the public markets. “The leverage we got was a viable IPO ready to go,” Tozer said. The Shire deal was done in 19 days. Tozer said the company chose to be acquired by Shire because of the volatility of the market.

    Show them the money. Companies increasingly must show the economic value of their technology. Clinical trial data is important not only to make the scientific case for a product, it can also make an important economic point to payers. Payers want to see how a new product will avoid cost when compared with the standard of care. “It’s really starting to affect how trials are designed,” Tozer said.

    More on clinical trials. ABH did a retrospective data analysis that showed that Dermagraft is cost effective after six months. That’s important to payers because their data show that people typically change insurance every two years. If a product doesn’t avoid cost before then, it won’t save the payer money.

    Sentiment: Strong Buy

  • Highlights
    - The global tissue engineering and regeneration market reached $17 billion in 2013. This market is expected to grow to nearly $20.8 billion in 2014 and $56.9 billion in 2019, a
    compound annual growth rate(CAGR) of 22.3%.
    - The North American market reached $7.3 billion in 2013. This market is expected to grow to nearly $9 billion in 2014 and $22.8 billion in 2019, a CAGR of 20.5%.
    - The Eupropean market reached nearly $6.9 billion in 2013. This market is expected to grow to nearly $8.3 billion in 2014 and $22.3 billion in 2019, a CAGR of 21.9%.

    Sentiment: Strong Buy

  • Reply to

    Huge Cytomedix advantage...

    by huskytrainer Sep 5, 2014 12:55 PM
    suemadrids suemadrids Sep 5, 2014 1:22 PM Flag

    Registry programs required for Coverage with Evidence Development (CED) are also on track at Cytomedix. By the end of the year, management expects to have roughly 1,000 patients enrolled in all four programs combined. The company currently has nine sales representatives out in the field promoting the product, with a goal of 30 by the end of the year. We went back and looked at the magnitude of business that Advanced BioHealing (ABH) was doing with Dermagraft in 2011 prior to its acquisition by Shire Pharmaceuticals. ABH had Dermagraft sales near $150 million annualized at the time of the deal, with about 100 full-time representatives. That equates to around $1.5 million per rep. If Cytomedix can match even half that efficiency, with a goal of 30 reps in the field at year-end 2014, Cytomedix could be doing $20-30 million in revenue with AutoloGel in 2015. That's an incredible ramp!

    Sentiment: Strong Buy

  • Reply to

    As of 5/15/14 very interesting...

    by suemadrids Sep 4, 2014 8:56 AM
    suemadrids suemadrids Sep 5, 2014 9:53 AM Flag

    Love this tream team too!

    Sentiment: Strong Buy

  • Reply to

    As of 5/15/14 very interesting...

    by suemadrids Sep 4, 2014 8:56 AM
    suemadrids suemadrids Sep 5, 2014 9:53 AM Flag

    Great DD, Thanks!

    Sentiment: Strong Buy

  • Reply to

    Sheedy and Dejoria facts...

    by biosearchone Sep 4, 2014 8:26 AM
    suemadrids suemadrids Sep 5, 2014 9:51 AM Flag

    Two game changers for sure!

    Sentiment: Strong Buy

  • Reply to

    As of 5/15/14 very interesting...

    by suemadrids Sep 4, 2014 8:56 AM
    suemadrids suemadrids Sep 4, 2014 8:57 AM Flag

    as stated by Husky...

    and they have not sold one single share...GLTA!
    Billionaire entrepreneur John Paul DeJoria made his fortune by cofounding mega-companies like Paul Mitchell hair products and Patron tequila. Now, he's trying to tackle the digital music arena with his new company Rok Mobile.

    Sentiment: Strong Buy

  • Name of Beneficial Owner Ownership (1) Class (1)

    Aldagen Holdings, LLC 14,029,927 (2) 11.5 %
    John Paul DeJoria 9,354,902 (3) 7.6 %
    Charles E. Sheedy 8,148,631 (4) 6.6 %
    Anson Investments Master Fund LP 8,471,392 (5) 6.8 %

    Sentiment: Strong Buy

CMXI
0.371-0.009(-2.37%)Oct 22 3:57 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.